An interventional study of Biological sample collection and immunomonitoring in B Cell Lymphoma and Multiple Mieloma, sponsored by Centre Henri Becquerel. Not yet recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.
Sponsored by Centre Henri Becquerel · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 95 studies in Lymphoma, B-Cell with a site in France — 20 open to participants now, 36 under way, 9 of them phase 3. Lymphoma, B-Cell · France.
Among the 95 studies in Lymphoma, B-Cell with a site in France, this one is the 62nd largest by planned enrollment of the 83 interventional ones that give a count, is one of 6 that started in 2026, is one of 7 with no phase, reaches primary completion later than 19 of the 35 other live ones, and was the 94th registered.
889 studies on the registry are indexed under Lymphoma, B-Cell; 289 are open to participants now.
Browse Lymphoma, B-Cell studies →20 of the 95 studies in Lymphoma, B-Cell with a site in France are open now. Recruiting first, the newest first:
Taiho Oncology, Inc. · Sites in France, United States, Australia and 3 more countries
Ages 18+
Eli Lilly and Company · Sites in France, United States, Australia and 9 more countries
Ages 18+
Daiichi Sankyo · Sites in France, United States, Italy and 1 more country
Ages 18+
The Lymphoma Academic Research Organisation · Sites in France
Ages 18+
Miltenyi Biomedicine GmbH · Sites in France, Germany, Italy and 1 more country
Ages 6 mo–17 yrs
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 209 Lymphoma, B-Cell studies recruiting now, 128 (61%) set no upper age limit and 61 (29%) stop at 75 or younger; 37 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
95 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 32 · Phase 2 40 · Phase 3 18 · Phase 4 1
First in 1996; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 45 is above the median of 34 across 775 interventional studies indexed under Lymphoma, B-Cell.
Median enrollment 103 across the 83 interventional studies, 249 across the 12 observational. Of the 56 that completed or were terminated, 18 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
54 of 95 have an industry lead sponsor. The 10 most frequent:
Centre Henri Becquerel is the lead sponsor of 59 studies on the registry; 17 are open to participants now.
Centre Henri Becquerel has 3 studies filed under Lymphoma, B-Cell — fewer than ten, so there is no comparison to draw.
12 of the studies in Lymphoma, B-Cell with a site in France that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04529772Phase 3Acerta Pharma BVA Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) | 2027-02-22 |
| NCT05254743Phase 3Loxo Oncology, Inc.A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | 2027-10 |
| NCT06047080Phase 3Hoffmann-La RocheAn Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma | 2027-10-01 |
| NCT04662255Phase 3Loxo Oncology, Inc.Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) | 2027-11 |
| NCT05463263Step Pharma, SASA Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas | 2026-12 |
Add all 12 to your calendar (.ics) → With an account.
Among the 95 studies in Lymphoma, B-Cell with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
CARBIOM is a single-centre, non-randomized interventional study involving additional biological sampling with minimal risks and constraints. Up to 45 adults with relapsed or refractory B-cell lymphoma or multiple myeloma who are scheduled to receive standard-of-care anti-CD19 or anti-BCMA CAR-T cells will be enrolled. The study will characterize CAR-positive and endogenous CAR-negative T-cell populations and T-cell receptor clonality at apheresis, in the CAR-T product, at Day 7 +/- 3 days and at Month 1 +/- 7 days. These findings will be related to treatment response, toxicities and relapse during 12 months of follow-up. The study hypothesis is that dynamic immunological and molecular characteristics measured along the CAR-T pathway are associated with early response, toxicity and relapse risk.
CARBIOM will enroll up to 45 participants to obtain 40 reinfused and evaluable participants at Month 1: 20 with B-cell lymphoma and 20 with multiple myeloma. CAR-T treatment and all disease-directed care remain standard of care and are not assigned by the study. Research procedures consist mainly of protocol-specific blood and stool sampling and laboratory analyses.
The primary analysis will longitudinally characterize CAR-positive and CAR-negative T-cell subpopulations, including expansion and decline, activation, differentiation, exhaustion, and T-cell receptor repertoire diversity, clonality and persistence. Analyses will use spectral flow cytometry and sequencing at apheresis, in the CAR-T bag before infusion, at Day 7 +/- 3 days and at Month 1 +/- 7 days. These parameters will be compared according to Month 1 response assessed using Lugano 2014 criteria for B-cell lymphomas or International Myeloma Working Group criteria for multiple myeloma.
Secondary and exploratory analyses will describe Month 3 response; 12-month progression-free survival, overall survival and non-relapse mortality; bridging therapy; CAR-T expansion and persistence by routine flow cytometry and digital PCR; cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome and prolonged cytopenias; PET-derived tumour burden; apheresis and CAR-T product features; tumour genomics, clonal haematopoiesis, antibiotic exposure and gut microbiota; and will establish a biobank of frozen cells, RNA and DNA for future ancillary analyses.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adults receiving standard-of-care anti-CD19 or anti-BCMA CAR-T cell therapy undergo protocol-specific biological sampling and longitudinal immunomonitoring. CAR-T treatment is not assigned by the study.
Procedure: Biological sample collection and immunomonitoring
Additional blood samples are collected at protocol-defined time points around standard-of-care CAR-T therapy, and stool samples are collected before lymphodepletion, at Month 1 and at Month 3. Analyses include spectral flow cytometry, T-cell receptor repertoire sequencing, routine flow cytometry, digital PCR, tumour molecular profiling and gut microbiota analyses. Standard-of-care CAR-T treatment is not assigned by the study.
Longitudinal CAR-positive and CAR-negative T-cell phenotype and T-cell receptor clonality associated with Month 1 response
Longitudinal characterisation of expansion and decline kinetics, activation, differentiation and exhaustion profiles, and T-cell receptor repertoire diversity, clonality and persistence by spectral flow cytometry and sequencing. Parameters will be compared between responders and non-responders at Month 1 using Lugano 2014 criteria for B-cell lymphomas or International Myeloma Working Group criteria for multiple myeloma.
Time frame: Apheresis; CAR-T product before infusion; Day 7 after infusion ; Month 1 after infusion. Therapeutic response is assessed at Month 1.
Secondary imaging outcomes after CAR-T cell infusion
Measures include Month 3 disease response PET-derived tumour burden
Time frame: Month 3 after CAR-T cell infusion
Secondary clinical outcomes after CAR-T cell infusion
12-month progression-free survival, overall survival and non-relapse mortality (in months)
Time frame: Month 12 after CAR-T cell infusion
Bridge treatment received
name of bridge treatment received before CAR-T cell infusion
Time frame: Month 1 after inclusion
secondary immunological outcome after CAR-T cell infusion
CAR-T expansion and persistence
Time frame: Month 1 after CAR-T cell infusion
Secondary micobiota outcome
gut microbiota findings
Time frame: Month 3 after CAR-T cell infusion
Secondary molecular outcome
Tumour molecular findings
Time frame: Inclusion
Start is estimated for Sep 2026; primary completion for Nov 2027, 13 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Henri Becquerel